Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

被引：22

作者：

Schmid, P. ^{[1
]}

Wysocki, P. J. ^{[2
]}

Ma, C. X. ^{[3
]}

Park, H. ^{[4
]}

Fernandes, R. ^{[5
]}

Lord, S. ^{[6
]}

Baird, R. D. ^{[7
]}

Prady, C. ^{[8
]}

Jung, K. H. ^{[9
]}

Asselah, J. ^{[10
]}

Huisden, R. ^{[11
]}

Stewart, R. ^{[12
]}

Heider, K. ^{[13
]}

Vukovic, P. ^{[14
]}

Denduluri, N. ^{[15
]}

Nowecki, Z. ^{[16
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] Jagiellonian Univ Med Coll, Dept Oncol, Krakow, Poland

[3] Washington Univ, Div Oncol, Dept Med, Sch Med, St Louis, MO USA

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[5] Western Univ, London Hlth Sci Ctr, Schulich Sch Med & Dent, Div Med Oncol,Dept Oncol, London, ON, Canada

[6] Univ Oxford, Div Med Sci, Dept Oncol, Oxford, Oxon, England

[7] Canc Res UK Cambridge Ctr, Dept Oncol, Cambridge, Cambs, England

[8] Sherbrooke Univ, Oncol, CISSS Monteregie Ctr, Ctr Integre Cancerol Monteregie, Greenfield Pk, PQ, Canada

[9] Univ Ulsan, Coll Med, Asan Med Ctr, Surg Oncol, Seoul, South Korea

[10] McGill Univ, Med Oncol, Ctr Hlth, Montreal, PQ, Canada

[11] AstraZeneca, Stat, Cambridge, England

[12] AstraZeneca, Translat Med, Oncol, Cambridge, England

[13] AstraZeneca, Late Phase Oncol R&D, Cambridge, England

[14] AstraZeneca, Late Phase Oncol, Cambridge, England

[15] AstraZeneca, Late Phase Oncol R&D, Gaithersburg, MD USA

[16] Maria Sklodowska Curie Natl Res Inst Oncol, Breast Surg, Warsaw, Poland

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.556

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

379MO

引用

页码：S337 / S337

页数：1